Skip to main content
. 2021 Jun 4;34(5):555–559. doi: 10.1080/08998280.2021.1930967

Table 3.

Proportion of patients with chronic kidney disease receiving apixaban who experienced thrombotic events

Outcome 5 mg BID 2.5 mg BID P valuea 10 mg BID
(n = 22) (n = 73) (n = 3)
Ischemic stroke 0 2 (3%) 1.00 0
Venous thromboembolism 1 (5%) 0 0.23 0
a

For comparison between 5.0 and 2.5 mg BID doses.